Clinical Trials Logo

Clinical Trial Summary

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04711200
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Saskia Oro, MD
Phone 0149812536
Email saskia.oro@aphp.fr
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 2022
Completion date September 2025

See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT02274428 - Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage Phase 1
Recruiting NCT04626583 - Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells Phase 1
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Recruiting NCT05602116 - ASC - Autism Study Phase 1
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT05204329 - Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Early Phase 1
Recruiting NCT05595681 - Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients. Phase 1
Not yet recruiting NCT03745417 - Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Enrolling by invitation NCT03876197 - Mesenchymal Stem Cells for Radiation-induced Xerostomia Phase 1/Phase 2
Terminated NCT04371393 - MSCs in COVID-19 ARDS Phase 3
Completed NCT04275024 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients N/A